# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Madam C. J. Walker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET019-SYN-TD
- Date: 1917-02-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Okonjo-Bell, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of the 24-hour ambulatory blood pressure and the repeat kidney tests, with a kidney ultrasound and a nephrology consultation. **S**

## History of present illness

Madam Walker returns two weeks after her first visit. She wore the ambulatory monitor for 24 hours on a day at home and has taken home readings morning and evening since, including on a three-day trip; the home average is 152/96. Her morning headaches continue on some days. She has taken no ibuprofen or naproxen. Her office sent the results of last year's executive physical: creatinine 1.18 mg/dL and protein 1+ on a urine dipstick, with no albumin test. She had the kidney ultrasound this morning and then met Dr. Achterberg of nephrology here. She has read about kidney disease and asked directly whether she is heading for dialysis, and what it would take to avoid it without giving up her travel. **S**

| Element | Detail |
|---|---|
| Ambulatory monitoring | 24-hour mean 149/94; daytime 154/98; night 140/88 |
| Home blood pressure | Average 152/96 over seven days, travel days included |
| Earlier results | Creatinine 1.18 mg/dL and dipstick protein 1+ about a year ago |
| Kidney ultrasound | This morning |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight loss |
| Neurological | Positive | Morning headaches on some days; no weakness or vision loss |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Genitourinary | Negative | No blood in the urine; gets up once at night to pass urine |
| Musculoskeletal | Negative | No joint pain or rash |

5 systems reviewed. **S**

## Current medications

- Losartan 50 mg oral tablet, one tablet each morning **S**
- Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 160/100 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 78.6 kg; BMI 29.6 kg/m². All vital signs are synthetic.

Urine albumin-to-creatinine ratio: 294 mg/g (high); Creatinine: 1.21 mg/dL (high); eGFR (CKD-EPI 1912, race-free): 55 mL/min/1.73 m² (low); Calcium: 9.4 mg/dL; Phosphate: 3.6 mg/dL; Parathyroid hormone (intact): 58 pg/mL; 25-hydroxyvitamin D: 31 ng/mL. All results are synthetic.

## Change since baseline

- Urine albumin-to-creatinine ratio: 286 mg/g (high) at baseline, 294 mg/g (high) at this visit **S**
- Creatinine: 1.22 mg/dL (high) at baseline, 1.21 mg/dL (high) at this visit **S**
- eGFR (CKD-EPI 1912, race-free): 54 mL/min/1.73 m² (low) at baseline, 55 mL/min/1.73 m² (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 160/100 (average of two readings), pulse 80; weight 78.6 kg |
| Cardiovascular | Regular rhythm; sustained apex beat; no murmur or bruit; no ankle swelling |
| Respiratory | Clear |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertension with chronic kidney disease** (I12.9). Ambulatory 24-hour mean 149/94 and daytime 154/98, with home readings 152/96 and clinic 160/100: stage 2 hypertension confirmed, without white-coat effect. Blood pressure falls by only 9% at night (a non-dipping pattern, common in kidney disease). Target-organ damage: left ventricular hypertrophy on the intake ECG, mild hypertensive retinopathy and albuminuria. TSH and A1c normal. Because she has CKD with albuminuria, a medicine that blocks the renin-angiotensin system comes first, whatever her race; she chose losartan over an ACE inhibitor because a cough would interfere with her speaking. **S**
   - Losartan 50 mg each morning at a fixed home time.
   - Potassium and creatinine in two weeks; increase to 100 mg then if they allow.
   - Goal below 130/80, lower toward 120 systolic if she feels well.
   - Echocardiogram at the next visit for the hypertrophy on ECG.
2. **Chronic kidney disease G3a A2** (N18.31). Repeat albumin-to-creatinine ratio 294 mg/g and creatinine 1.21 mg/dL (eGFR 55 by the race-free CKD-EPI 1912 equation). With protein on a dipstick and a similar creatinine a year ago, the abnormality has lasted more than three months, so this is chronic kidney disease, G3a A2: high risk on the KDIGO heat map. The equation used until recently, with a race coefficient, would have reported her eGFR as about 60 and could have delayed this diagnosis. Ultrasound: kidneys 10.4 and 10.6 cm, normal cortex, mildly increased echogenicity, no obstruction or stones. Urinalysis at intake showed 1+ protein without blood and a bland sediment. Calcium 9.4 mg/dL, phosphate 3.6 mg/dL, parathyroid hormone 58 pg/mL and 25-hydroxyvitamin D 31 ng/mL are normal. 5-year kidney failure risk 1.6% (KFRE): low, and she was told so plainly. Dr. Achterberg judges hypertensive kidney disease most likely. **S**
   - Empagliflozin 10 mg each morning.
   - Sick-day rules for losartan and empagliflozin written on a card for her bag.
   - Hepatitis B, hepatitis C and HIV tests today, as Dr. Achterberg advised.
   - APOL1 genetic testing explained; she will decide after reading about it.
   - Urine albumin again in about three months.
3. **Hyperlipidemia** (E78.5). LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations, intermediate, with CKD as a risk enhancer. KDIGO advises a statin for adults with CKD from 50, or younger at higher risk; the ACC/AHA guideline favors one at intermediate risk with a risk enhancer. After reviewing the numbers she chose to start. **S**
   - Atorvastatin 20 mg daily.
   - Lipid panel and ALT in four to twelve weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings) | Every visit | Completed today | 160/100 |
| Examination | 24-hour ambulatory blood pressure monitoring | At diagnosis | Completed today | 24-hour mean 149/94, daytime 154/98, night 140/88; non-dipping |
| Self-management | Home blood pressure readings | Two readings morning and evening for seven days to confirm and after each change; then twice a week, travel days included | Completed today | Seven-day average 152/96 |
| Examination | Weight and BMI | Every visit | Completed today | 78.6 kg, BMI 29.6 |
| Laboratory | Potassium, bicarbonate, creatinine and eGFR (CKD-EPI 1912, race-free) | Two to four weeks after starting or increasing losartan or empagliflozin; then every six months | Completed today | Creatinine 1.21 mg/dL, eGFR 55 (CKD-EPI 1912, race-free); potassium 4.4 mmol/L two weeks ago; panel booked in two weeks after starting losartan and empagliflozin |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; about three months after a treatment change; then every six months for G3a A2 | Completed today | 294 mg/g, confirming 286 at intake |
| Laboratory | Calcium, phosphate and parathyroid hormone | At diagnosis of G3a, then every 6 to 12 months | Completed today | Calcium 9.4, phosphate 3.6 mg/dL; parathyroid hormone 58 pg/mL |
| Laboratory | 25-hydroxyvitamin D | At baseline | Completed today | 31 ng/mL |
| Laboratory | Urinalysis with microscopy | At diagnosis | Up to date | At intake: 1+ protein, no blood, bland sediment |
| Imaging | Kidney ultrasound | Once, at the diagnosis of CKD | Completed today | Normal-sized kidneys, mildly increased echogenicity, no obstruction |
| Laboratory | Hemoglobin | Yearly in CKD G3 | Up to date | 12.4 g/dL at intake |
| Survey | Kidney failure risk equation (4-variable), 2- and 5-year | Yearly for G3 to G5 | Completed today | 5-year risk 1.6%, 2-year risk under 1% |
| Survey | 10-year ASCVD risk (Pooled Cohort Equations) | Yearly | Completed today | 7.9%, intermediate; CKD a risk enhancer |
| Laboratory | Lipid panel and ALT | 4 to 12 weeks after starting a statin, then yearly | Up to date | LDL 174 mg/dL at intake; atorvastatin started today |
| Examination | Baseline ECG, TSH and A1c | At the diagnosis of hypertension | Up to date | Done at intake: LVH by voltage; TSH 1.9; A1c 5.4% |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or LVH on ECG | Ordered | Booked for the next visit |
| Examination | Fundus examination | Yearly | Up to date | At intake: mild arteriolar narrowing, no hemorrhages |
| Medication safety | Medicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zones | Every visit | Completed today | No NSAIDs; sick-day card given; losartan, empagliflozin and atorvastatin explained, including genital hygiene on empagliflozin |
| Self-management | Sodium and diet counseling | Every visit | Completed today | Video session with the dietitian booked before her next trip |
| Referral | Nephrology review | At diagnosis; then about six months, by video if she prefers | Completed today | Seen by Dr. Achterberg today |

## Goal progress

- Blood pressure below 130/80 mmHg in the clinic and at home within six months, lower toward a systolic of 120 if well tolerated. In progress; target 1917-08-17. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% within six months. In progress; target 1917-08-17. **S**
- Kidney function stable, without a fall in eGFR of more than 30% after starting treatment. In progress; target 1917-08-17. **S**
- Sodium under 2 g a day using foods she likes, at home and on the road. In progress; target 1917-08-17. **S**
- LDL cholesterol lower by at least 30%. In progress; target 1917-04-27. **S**
- Care that fits her work: every check scheduled around her travel, by her choice. In progress; target 1917-08-17. **S**

## Medication changes

- Started: Losartan 50 mg oral tablet, one tablet each morning **S**
- Started: Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery **S**
- Started: Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021), Inker LA et al., N Engl J Med 2021
- A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021), National Kidney Foundation and American Society of Nephrology (Am J Kidney Dis 2022)
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018), American College of Cardiology and American Heart Association (Circulation 2019)
- CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026), Aether Forge

## Follow-up

- Potassium and creatinine in two weeks with the echocardiogram. Home readings twice a day for a week after starting, then twice a week. Call for dizziness, fainting, vomiting or diarrhea (hold losartan and empagliflozin), or swelling of the lips or tongue. **S**
- Next scheduled visit 1917-03-09: two-week check of potassium and creatinine after starting losartan and empagliflozin, home readings, and the echocardiogram. **S**
